Dare Bioscience, Inc. (DARE) stock
DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.58−0.07 (-11.13%)
Close on Nov 16, 2026Market cap $8.93MP/E –Yield –
Dare Bioscience ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Dare Bioscience's ebitda for the twelve months ending Jun 30, 2026 was -$8.98M. For fiscal 2025 it was -$11.92M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.92M | – |
| FY2024 | Dec 31, 2024 | -$23.41M | – |
| FY2016 | Dec 31, 2016 | -$369.59K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.40M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$936.87K | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.37M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.38M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.67M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.34M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.01M | -9790.5% |
| Q2 FY2017 | Jun 30, 2017 | -$465.62K | – |
| Q1 FY2017 | Mar 31, 2017 | -$162.46K | – |
| Q4 FY2016 | Dec 31, 2016 | -$122.64K | – |
| Q3 FY2016 | Sep 30, 2016 | $62.04K | – |
See a number that looks wrong?